Skip to main content

Myasthenia Gravis clinical trials at UC Irvine

7 in progress, 6 open to eligible people

Showing trials for
  • Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

    open to eligible people ages 18 years and up

    This study is researching an experimental combination treatment with pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized myasthenia gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with gMG. The study is looking at several other research questions, including: - What side effects may happen from taking the study drugs - How the study drugs work inside the body - How much study drugs are in the blood at different times - Whether the body makes antibodies against pozelimab and cemdisiran (which could make the drugs less effective or could lead to side effects)

    Irvine, California and other locations

  • Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

    open to eligible people ages 18 years and up

    This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

    Irvine, California and other locations

  • KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis

    open to eligible people ages 18-75

    A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Myasthenia Gravis

    Orange, California and other locations

  • Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

    open to eligible people ages 18 years and up

    Muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) is a rare but potentially severe disease, in which patients develop pathogenic autoantibodies that specifically target the MuSK protein in the neuromuscular junction. This phase 1 study is being conducted to evaluate the safety of various dosing regimens of an investigational cell therapy, MuSK-CAART, that can be given to patients with anti-MuSK antibody positive Myasthenia Gravis (MuSK MG), who have active disease. Various dosing regimens of MuSK-CAART alone, in combination with cyclophosphamide (CY), and in combination with CY and fludarabine (FLU) will be evaluated. Treatment with MuSK-CAART may potentially lead to complete and durable remission of disease.

    Orange, California and other locations

  • RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

    open to eligible people ages 18-70

    RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis

    Orange, California and other locations

  • Exploring Outcomes and Characteristics of Myasthenia Gravis 2

    open to eligible people ages 18 years and up

    The goal of this prospective observational study is to create a network repository of clinical data and biological samples to help researchers learn more about myasthenia gravis.

    Irvine, California and other locations

  • Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

    Sorry, not currently recruiting here

    Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.

    Orange, California and other locations

Our lead scientists for Myasthenia Gravis research studies include .

Last updated: